Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS

Mary Jeanne Kreek, Don Des Jarlais, Christian L. Trepo, David M. Novick, Abu Abdul-Quader, Jayanthi Raghunath

Research output: Contribution to journalArticle

Abstract

Parenteral drug abusers are the second largest group at risk for developing AIDS (25% of US cases) and a major risk group for infection with both hepatitis B virus (HBV) and the HBV-dependent RNA hepatitis delta virus (HDV). This study was conducted to determine the prevalence in 1984–1985 and relationships of HDV and HBV infections in 372 unselected parenteral drug abusers without AIDS or symptoms related to human immunodeficiency virus type 1 (HIV1) infection (but 49% of whom were positive for HIV-1 antibodies) and in 53 drug abusers hospitalized with AIDS. The prevalence of HDV markers in the combined study groups was 20%;81% of study subjects with hepatitis B surface antigenemia (HBsAg) had one marker for HDV infection. Significant differences were found between patients with and without AIDS with respect to the prevalence of hepatitis delta antigen (5.7% vs. 0.8%, P<.05) and antibody (0 vs. 21.4%, P <.01) and HBsAg (15.1% vs. 5.1%, P <.05). The significantly higher prevalence of hepatitis delta antigen and HBsAg in subjects with AIDS suggests that persistence or reactivation of these viruses is significantly greater among parenteral drug abusers with AIDS than among those without AIDS. These findings, along with the absence of hepatitis delta antibodies in the drug abusers with AIDS, are probably related to the profound general immunosuppression that occurs in AIDS.

Original languageEnglish (US)
Pages (from-to)538-541
Number of pages4
JournalJournal of Infectious Diseases
Volume162
Issue number2
DOIs
StatePublished - Jan 1 1990

Fingerprint

Hepatitis D
Drug Users
Acquired Immunodeficiency Syndrome
Hepatitis Delta Virus
Virus Diseases
Hepatitis delta Antigens
Hepatitis B
Hepatitis B virus
HIV-1
Hepatitis Antibodies
HIV Antibodies
RNA Viruses
Immunosuppression
Viruses

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Cite this

Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS. / Kreek, Mary Jeanne; Des Jarlais, Don; Trepo, Christian L.; Novick, David M.; Abdul-Quader, Abu; Raghunath, Jayanthi.

In: Journal of Infectious Diseases, Vol. 162, No. 2, 01.01.1990, p. 538-541.

Research output: Contribution to journalArticle

Kreek, Mary Jeanne ; Des Jarlais, Don ; Trepo, Christian L. ; Novick, David M. ; Abdul-Quader, Abu ; Raghunath, Jayanthi. / Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS. In: Journal of Infectious Diseases. 1990 ; Vol. 162, No. 2. pp. 538-541.
@article{38ef919b3f714962868f6491c7f34778,
title = "Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS",
abstract = "Parenteral drug abusers are the second largest group at risk for developing AIDS (25{\%} of US cases) and a major risk group for infection with both hepatitis B virus (HBV) and the HBV-dependent RNA hepatitis delta virus (HDV). This study was conducted to determine the prevalence in 1984–1985 and relationships of HDV and HBV infections in 372 unselected parenteral drug abusers without AIDS or symptoms related to human immunodeficiency virus type 1 (HIV1) infection (but 49{\%} of whom were positive for HIV-1 antibodies) and in 53 drug abusers hospitalized with AIDS. The prevalence of HDV markers in the combined study groups was 20{\%};81{\%} of study subjects with hepatitis B surface antigenemia (HBsAg) had one marker for HDV infection. Significant differences were found between patients with and without AIDS with respect to the prevalence of hepatitis delta antigen (5.7{\%} vs. 0.8{\%}, P<.05) and antibody (0 vs. 21.4{\%}, P <.01) and HBsAg (15.1{\%} vs. 5.1{\%}, P <.05). The significantly higher prevalence of hepatitis delta antigen and HBsAg in subjects with AIDS suggests that persistence or reactivation of these viruses is significantly greater among parenteral drug abusers with AIDS than among those without AIDS. These findings, along with the absence of hepatitis delta antibodies in the drug abusers with AIDS, are probably related to the profound general immunosuppression that occurs in AIDS.",
author = "Kreek, {Mary Jeanne} and {Des Jarlais}, Don and Trepo, {Christian L.} and Novick, {David M.} and Abu Abdul-Quader and Jayanthi Raghunath",
year = "1990",
month = "1",
day = "1",
doi = "10.1093/infdis/162.2.538",
language = "English (US)",
volume = "162",
pages = "538--541",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Contrasting prevalence of delta hepatitis markers in parenteral drug abusers with and without AIDS

AU - Kreek, Mary Jeanne

AU - Des Jarlais, Don

AU - Trepo, Christian L.

AU - Novick, David M.

AU - Abdul-Quader, Abu

AU - Raghunath, Jayanthi

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Parenteral drug abusers are the second largest group at risk for developing AIDS (25% of US cases) and a major risk group for infection with both hepatitis B virus (HBV) and the HBV-dependent RNA hepatitis delta virus (HDV). This study was conducted to determine the prevalence in 1984–1985 and relationships of HDV and HBV infections in 372 unselected parenteral drug abusers without AIDS or symptoms related to human immunodeficiency virus type 1 (HIV1) infection (but 49% of whom were positive for HIV-1 antibodies) and in 53 drug abusers hospitalized with AIDS. The prevalence of HDV markers in the combined study groups was 20%;81% of study subjects with hepatitis B surface antigenemia (HBsAg) had one marker for HDV infection. Significant differences were found between patients with and without AIDS with respect to the prevalence of hepatitis delta antigen (5.7% vs. 0.8%, P<.05) and antibody (0 vs. 21.4%, P <.01) and HBsAg (15.1% vs. 5.1%, P <.05). The significantly higher prevalence of hepatitis delta antigen and HBsAg in subjects with AIDS suggests that persistence or reactivation of these viruses is significantly greater among parenteral drug abusers with AIDS than among those without AIDS. These findings, along with the absence of hepatitis delta antibodies in the drug abusers with AIDS, are probably related to the profound general immunosuppression that occurs in AIDS.

AB - Parenteral drug abusers are the second largest group at risk for developing AIDS (25% of US cases) and a major risk group for infection with both hepatitis B virus (HBV) and the HBV-dependent RNA hepatitis delta virus (HDV). This study was conducted to determine the prevalence in 1984–1985 and relationships of HDV and HBV infections in 372 unselected parenteral drug abusers without AIDS or symptoms related to human immunodeficiency virus type 1 (HIV1) infection (but 49% of whom were positive for HIV-1 antibodies) and in 53 drug abusers hospitalized with AIDS. The prevalence of HDV markers in the combined study groups was 20%;81% of study subjects with hepatitis B surface antigenemia (HBsAg) had one marker for HDV infection. Significant differences were found between patients with and without AIDS with respect to the prevalence of hepatitis delta antigen (5.7% vs. 0.8%, P<.05) and antibody (0 vs. 21.4%, P <.01) and HBsAg (15.1% vs. 5.1%, P <.05). The significantly higher prevalence of hepatitis delta antigen and HBsAg in subjects with AIDS suggests that persistence or reactivation of these viruses is significantly greater among parenteral drug abusers with AIDS than among those without AIDS. These findings, along with the absence of hepatitis delta antibodies in the drug abusers with AIDS, are probably related to the profound general immunosuppression that occurs in AIDS.

UR - http://www.scopus.com/inward/record.url?scp=0025296063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025296063&partnerID=8YFLogxK

U2 - 10.1093/infdis/162.2.538

DO - 10.1093/infdis/162.2.538

M3 - Article

VL - 162

SP - 538

EP - 541

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -